Abstract. Pure-type clear cell carcinoma (CCC) has been recognized as a distinct subtype of ovarian cancer, showing a resistance to chemotherapy and resulting in poor prognosis. Our aim was to evaluate the effects of complete surgical procedures followed by adjuvant chemotherapy for CCC patients whose tumors were confined to the ovary (pT1M0). During the period of 1987-2005, 56 patients with stage I CCC were identified and two cases were excluded due to retroperitoneal lymph node metastasis. A total of 54 patients were enrolled in the study and divided into two groups: Group A (n=38, 1993-2005) underwent complete surgical staging including pelvic and para-aortic lymphadenectomy. Group B (n=16, 1987Group B (n=16, -1992) underwent a hysterectomy, bilateral salpingo-oopherectomy, omentectomy without comprehensive lymphadenectomy. Every patient received six courses of adjuvant chemotherapy using a platinum agent. Survival analysis was estimated by the Kaplan-Meier method and prognostic factors were evaluated using a Cox regression model. The clinical characteristics of the two groups were similar, except for the rate of conventional platinum-based chemotherapy (p=0.02). Multiple regression survival analysis revealed that the completion of a comprehensive staging operation was the only independent factor for progressionfree survival of stage I CCC patients (p=0.03) and that the chemotherapeutic regimen was not a prognostic factor (p=0.43). The present study indicates that we should accomplish complete surgical staging procedures for CCC confined to the ovary.
Introduction
Ovarian carcinoma is now the leading cause of death in all gynecological malignancies in most developed countries, despite recent improvement of treatment modalities (1, 2) . The poor prognosis was accounted for largely by a high frequency of advanced cases at the time of diagnosis, although a paclitaxel-based regimen achieved a high clinical response rate of ~70% (3) . The regimen is recognized as the gold standard for ovarian cancer, showing a remarkable impact for not only primary ovarian tumors but also recurrent tumors (4) (5) (6) . On the other hand, clear cell carcinoma (CCC) of the ovary initially termed by Schiller (7) and characterized by WHO (8) has been identified as having a distinctive behavior in comparison with other histological subtypes. Many publications confirmed that the most distinct difference of CCC tumors was a significant lower rate of response to conventional platinum-based chemotherapy (9) (10) (11) (12) . Similarly, the response of paclitaxel-based regimen for CCC was from 22 to 56% (13) (14) (15) and the impact for survival improvement was not clearly determined (16, 17) . Irinotecan hydrochloride, a semisynthetic derivative of camptothecin, has been reported to have a potential therapeutic effect on CCC (18) (19) (20) , though there has been no large clinical trial confirming survival benefits. The second distinct difference was that CCC tumors showed a high frequency of stage I tumors, roughly accounting for 50% of all cases (11, 17, 21) . Surgical staging including lymphadenectomy was inevitable for the FIGO staging system (22) , though there has been limited studies showing a significant benefit in the patients with tumors in their early stages. Moreover, a clinical significance of complete surgical staging followed by adjuvant chemotherapy for stage I CCC tumors has not yet been established. The aim of our study was to evaluate the effect of staging procedures upon the survival of clinical stage I CCC patients. Patients were routinely monitored as follows; 1 through to 6 months, physical examination and serum tumor marker estimation including CA125 every month, CT or MRI images every 3 months; month 7 to year 2, physical examination and serum tumor marker estimation including CA125 every 1-2 months, CT or MRI images every 6 months; years 3 through to 5, physical examination and serum tumor marker estimation including CA125 every 3-6 months, CT or MRI images annually, years over 6, physical examination and serum tumor marker estimation including CA125 annually, CT if indicated. Additional clinical assessments were performed as indicated clinically.
Materials and methods

Patients
The progression of the disease (PD) was defined as the appearance of a new lesion evaluated by a CT of the chest/abdomen or pelvic MR images. The serum levels of tumor markers including CA125 were not used for survival analysis in the present study. The time to relapse was defined as the interval from the date of primary surgery until the date of PD. Survival duration was determined as the time from the date of primary surgery until death or the date of the last follow-up contact.
Statistical methods. The Kaplan-Meier method was used for the calculation of patient survival distribution. The significance of the survival distribution in each group was tested by the log-rank test. The Chi-square test and the Student's t-test for unpaired data were used for statistical analysis. A P-value of <0.05 was considered statistically significant. The Stat View software ver.5.0 (SAS Institution Inc., Cary, NC, USA) was used to analyze the data.
Results
In total, 54 cases with clinical stage I tumors (pT1M0) were enrolled in the present study. The median age was 52 years (range: 36-75) and the median follow-up duration was 48 months (range: 2-166) for relapse-free survival and 50 months (range: 8-166) for overall survival. The median number of the removed lymph nodes in Group A were 35 (range: 19-70) in the pelvic nodes and 20 (range: 12-44) in the para-aortic nodes, respectively.
The characteristics of the patients with ovarian CCC are shown in Table I . Fifteen patients (28%) had stage I tumors and 39 patients (72%) had stage Ic tumors. In 39 stage Ic tumors, 19 cases (49%) had malignant ascites or positive peritoneal washing and tumors in 20 cases (51%) had ruptured during operation. Clinical characteristics of the two groups were similar, although CAP therapy was more frequently used in Group B (p=0.02). In Group A, regimens used were CAP in 10 cases (26%), paclitaxel and platinum in 5 cases (13%) and irinotecan hydrochloride and platinum in 23 cases (61%). In Group B, CAP was used in 11 cases (69%) and others in 5 cases (31%).
Two-year and 5-year relapse-free survival was 84 and 84% in Group A and 71 and 64% in Group B. Two-year and 5-year overall survival was 86 and 82% in Group A and 86 and 72% in Group B, respectively. Recurrent tumors were detected in 4 cases (11%) of Group A; two (6%) in the intra-abdominal cavity, one (3%) in the pelvic nodes and one (3%) in the mediastinal nodes. Four cases (25%) from Group B were detected to have recurrent tumors: two (13%) in the pelvic nodes and two (13%) in the intra-abdominal cavity. Relapsefree survival according to the pT status is shown in Fig. 1 . The pT1a and pT1c tumors in Group B were slightly lower than those tumors in Group B, though the differences were not statistically significant.
A multiple regression analysis was performed in order to detect prognostic factors for relapse-free survival of stage I CCC. Values of age, performance status, stage distribution, ascites or washing status, group distribution and chemotherapy were compared. As a result, group distribution was the only independent prognostic factor for relapse-free survival (Group A vs Group B, hazard ratio, 5.72; p=0.03). Age, performance status, stage distribution and chemotherapy were not significant prognostic factors (Table II) . A multiple regression analysis was performed for detecting the prognostic factors for overall survival of stage I CCC using the same values as described in Table II , though there were no significant prognostic factors (data not shown).
Discussion
The number of removed nodes determines the radicality of lymphadenectomy. One report suggested that ~81 lymph nodes (range, 49-128) are located between the pelvis and the aortic area; 50 at the pelvis and 31 at the aorta (23). Pereira et al reported that ~25 pelvic lymph nodes and 13 aortic lymph nodes are adequate for the detection of nodal involvement in epithelial ovarian cancer (24) . According to these criteria, insufficient lymphadenectomy was documented in 4 cases (11%) in the pelvis and 2 cases (5%) in the para-aortic nodes, suggesting that lymphadenectomy in our series of CCC could be adequate for further evaluation.
The incidence of positive retroperitoneal lymph nodes in each subtype of stage I (pT1) ovarian cancer was relatively high, ranging up to 20% (25) (26) (27) . A report (28) demonstrated that serous tumors had a higher incidence of lymph node metastasis than non-serous tumors and another report (20) demonstrated that lymph node involvement of the CCC disease was observed in 9.1% in pT1a and 7.1% in pT1c tumors. It is suggested that the CCC tumors have a lower incidence of lymphatic involvement compared with other histological subtypes.
In the early stages of ovarian cancer, the significance of retroperitoneal lymph node status upon survival was not determined. While certain reports showed a positive relationship with node status and survival (27, 29, 30) , others showed survival similarity between node-positive andnegative tumors (31, 32) . A large study with completely staged CCC disease revealed that the positive lymph node was significantly correlated with worse prognosis in pT1 tumors (20) . However, another large study concluded that lymphadenectomy significantly improved 5-year survival of non-clear cell type tumors and that the survival of CCC cases were not improved by lymphadenectomy (33) . This discrepancy might be explained by the difference of sensitivity to postoperative chemotherapy or by an unbalanced distribution of the subtypes of stage I tumors, because positive Table I . Characteristics of the patients with ovarian clear cell carcinoma confined to the ovary (pT1M0). peritoneal cytology was correlated with a worse prognostic in FIGO stage I tumors (20) .
-----------------------------------------------------------------------------------------------------Stage Group A (n=38) Group B (n=16) P-value -----------------------------------------------------------------------------------------------------
The tumor relapse in the pelvic or para-aortic nodes were possibly less observed in Group A (3%) than in Group B (13%, p=0.14). Although the difference was not significant, relapse at the lymph nodes might have been reduced by comprehensive lymphadenectomy. Recurrence of intraabdominal space occurred in 8% in Group A and 13% in Group B, suggesting the similarity of the abdominal recurrence rates of the two groups.
The study, called Adjuvant ChemoTherapy in Ovarian Neolasm (ACTION), documented that the benefits of adjuvant chemotherapy was limited in non-optimally staged early-stage ovarian cancer (34) . This study included only 14% of CCC, and the distribution of the histological subtypes might have confused the results due to chemosensitivity difference. In the present study, complete surgical staging was the only significant factor for relapse-free survival of stage I CCC tumors. This might support the therapeutic effects of lymphadenectomy of ovarian neoplasms, especially CCC whose tumors show a relative resistance to anti-cancer drugs. Several explanations are possible for the improvement of survival: comprehensive lymphadenectomy might remove the micrometastasis disease which could not be detected by conventional histopathological methods (35, 36) and the significance would be greater if the lesion included chemoresistant clones. Otherwise, the significance was obvious simply because Group B contained some cases of true stage IIIc (pT1N1) disease. Based on a previous study, there is the possibility of contamination of up to 10% of stage I CCC cases whose lymph nodes have metastasis, thus the cases would worsen the prognosis of non-surgically staged disease. The results suggest that comprehensive lymphadenectomy for clinical stage I CCC cases is associated not only with diagnostic significance but also with therapeutic effects. Thus, we could not easily omit lymphadenenctomy even for the fertility-sparing operation if the tumor of the patient was diagnosed as CCC.
Complications with lymphadnectomy are to some extent unavoidable. Actually, median operation time was longer and more cases required a blood transfusion (37) . Nevertheless, the need of maximal optimal surgery including lymphadenectomy is emphasized by the evidence that the extent of lymphadenectomy increased the survival rates of stage I ovarian cancer patients (33) .
As every case received chemotherapy, we could not compare the presence or absence of the therapy. In our retrospective study, however, there was no significant difference in regimens of postoperative chemotherapy for relapse-free and overall survival. We have to wait for the results of a large international study which has started to compare irinotecan hydrochloride plus cisplatin with paclitaxel plus carboplatin for postoperative chemotherapy for CCC (GCIG/JGOG 3017).
In the aspect of molecular characteristics as well as clinical behavior, it is hypothesized that CCC belongs to a different entity from other histological subtypes of ovarian carcinoma. There are many publications supporting this hypothesis and molecular markers such as HNF-1ß (38, 39) , PPM1D (40) , APPBP2 (40), WT1(41), WT1-AS(41) and ABCF2 (42) might be used for targets of CCC in the near future. Table II . Multiple regression survival analysis for the patients with ovarian clear cell carcinoma confined to the ovary (pT1M0).
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a CAP, cyclophosphamide + doxorubicin + cisplatin.
The present study implied there are diagnostic and prognostic effects in complete surgical staging for the treatment of CCC confined to the ovary. However, this was a limited retrospective study and could not suggest the significant therapeutic impact of comprehensive lymphadenectomy plus chemotherapy upon survival. We need to further investigate the therapeutic effects of comprehensive lymphadenectomy in a large prospective study using single regimen, which would be selected by a large study, such as GCIG/JGO3017.
